These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 16708855)

  • 21. [Update: treatment of multiple sclerosis].
    Kümpfel T; Hohlfeld R
    MMW Fortschr Med; 2009 Mar; 151(13):70-2. PubMed ID: 19504824
    [No Abstract]   [Full Text] [Related]  

  • 22. Modern multiple sclerosis treatment - what is approved, what is on the horizon.
    Pilz G; Wipfler P; Ladurner G; Kraus J
    Drug Discov Today; 2008 Dec; 13(23-24):1013-25. PubMed ID: 18775508
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Re: early relapses after the first dose of natalizumab in active multiple sclerosis.
    Haartsen J; Marriott M; Butzkueven H
    Mult Scler; 2009 Apr; 15(4):520. PubMed ID: 19324983
    [No Abstract]   [Full Text] [Related]  

  • 24. Cladribine: an investigational immunomodulatory agent for multiple sclerosis.
    Brousil JA; Roberts RJ; Schlein AL
    Ann Pharmacother; 2006 Oct; 40(10):1814-21. PubMed ID: 16985095
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Natalizumab use in pediatric multiple sclerosis.
    Huppke P; Stark W; Zürcher C; Huppke B; Brück W; Gärtner J
    Arch Neurol; 2008 Dec; 65(12):1655-8. PubMed ID: 19064754
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Another complication of natalizumab treatment? Taking the challenge.
    Goebels N; Kappos L
    Ann Neurol; 2009 Sep; 66(3):264-6. PubMed ID: 19798646
    [No Abstract]   [Full Text] [Related]  

  • 27. Biological agents: new drugs, old problems.
    Muñoz-Cano R; Carnés J; Sanchez-Lopez J; Saiz A; Bartra J; Lopez-Matas MA; Picado C; Valero A
    J Allergy Clin Immunol; 2010 Aug; 126(2):394-5. PubMed ID: 20579714
    [No Abstract]   [Full Text] [Related]  

  • 28. [New drugs; natalizumab].
    van Bronswijk H; Dubois EA; van Gerven JM; Cohen AF
    Ned Tijdschr Geneeskd; 2008 Mar; 152(9):499-500. PubMed ID: 18389881
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.
    Stüve O; Marra CM; Bar-Or A; Niino M; Cravens PD; Cepok S; Frohman EM; Phillips JT; Arendt G; Jerome KR; Cook L; Grand'Maison F; Hemmer B; Monson NL; Racke MK
    Arch Neurol; 2006 Oct; 63(10):1383-7. PubMed ID: 17030653
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The curtain is drawn for both natalizumab and fingolimod (FTY720): a new era of multiple sclerosis therapy has arrived.
    Weissert R
    Expert Rev Neurother; 2006 Nov; 6(11):1587-90. PubMed ID: 17144774
    [No Abstract]   [Full Text] [Related]  

  • 31. Immunomodulating drugs in multiple sclerosis: compliance, satisfaction and adverse effects evaluation in a German multiple sclerosis population.
    Twork S; Nippert I; Scherer P; Haas J; Pöhlau D; Kugler J
    Curr Med Res Opin; 2007 Jun; 23(6):1209-15. PubMed ID: 17559722
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Natalizumab: bound to rebound?
    Schiess N; Calabresi PA
    Neurology; 2009 Feb; 72(5):392-3. PubMed ID: 19188569
    [No Abstract]   [Full Text] [Related]  

  • 33. [Natalizumab in multiple sclerosis].
    Rajda C; Bencsik K; Vécsei L;
    Ideggyogy Sz; 2008 May; 61(5-6):204-8. PubMed ID: 18567397
    [No Abstract]   [Full Text] [Related]  

  • 34. Alemtuzumab: new indication. First line treatment of chronic lymphocytic leukaemia: continue to use oral chlorambucil.
    Prescrire Int; 2009 Apr; 18(100):60. PubMed ID: 19585719
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Natalizumab for multiple sclerosis?
    Drug Ther Bull; 2008 Sep; 46(9):69-72. PubMed ID: 18784381
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiple sclerosis: interferon beta for some serious forms.
    Prescrire Int; 2007 Dec; 16(92):252-7. PubMed ID: 18092425
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is natalizumab overshooting its rebound?
    Fox RJ; Kappos L
    Neurology; 2008 Mar; 70(13 Pt 2):1073-4. PubMed ID: 18362270
    [No Abstract]   [Full Text] [Related]  

  • 38. [Treatment of multiple sclerosis--now and in future. The Danish Multiple Sclerosis Society and the Danish Multiple Sclerosis Group].
    Sellebjerg FT; Sørensen PS;
    Ugeskr Laeger; 2007 Mar; 169(12):1121. PubMed ID: 17394832
    [No Abstract]   [Full Text] [Related]  

  • 39. Balancing risk and reward: the question of natalizumab.
    Hauser SL; Johnston SC
    Ann Neurol; 2009 Sep; 66(3):A7-8. PubMed ID: 19810091
    [No Abstract]   [Full Text] [Related]  

  • 40. [Advantages in diagnostic and treatment of MS].
    Hjaltason H
    Laeknabladid; 2008 May; 94(5):359. PubMed ID: 18460730
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.